Overview

Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
0
Participant gender:
All
Summary
Concomitant chemoradiotherapy improves overall survival in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) compared to radiotherapy alone. Cisplatin 100 mg/m2 at day 1, 22 and 43 is widely used but results in considerable acute and late toxicity. Three cycles of carboplatin plus 5-fluorouracil (5-FU) is an accepted alternative but both chemotherapy regimens have not been compared prospectively. The aim of this study is to compare tolerability, efficacy, toxicity and quality of life in patients with LA-HNSCC treated with concomitant cisplatin and carboplatin plus 5-FU.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Medical Center Groningen
Collaborator:
VU University Medical Center
Treatments:
Carboplatin
Cisplatin
Fluorouracil
Criteria
Inclusion Criteria:

- Stage III-IV LA-HNSCC of hypopharynx, oropharynx, larynx, oral cavity

- Primary treatment with concomitant chemoradiotherapy consisting of three-weekly
cisplatin or carboplatin plus 5-FU

- Age ≤ 70 years

- No previous treatment for head and neck cancer

- No distant metastases

Exclusion Criteria:

- Previous treatment for head and neck cancer

- Distant metastases